• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Vera Therapeutics (VERA) Stock Dropped, So What Is Behind The Move?

    Simply Wall St·10/25/2026 13:31:08
    语音播报

    Vera Therapeutics (VERA) drew fresh attention after releasing final Phase III ORIGIN 3 data for TRUTAKNA in IgA nephropathy, showing statistically significant efficacy across all prespecified endpoints, alongside a generally favorable safety profile.

    Against this backdrop, Vera Therapeutics’ share price has retreated, with the 30-day share price return down 13.98% and the year-to-date share price return down 42.43%, even though the three-year total shareholder return is up 180.46%. This indicates longer term momentum that has recently cooled.

    Spot opportunities around Vera Therapeutics by scanning a curated set of late-stage biotech and healthcare plays through the 34 healthcare AI stocks.

    Bulls point to Vera Therapeutics’ late-stage data and first commercial steps, while bears focus on the sharp pullback and ongoing losses. As you weigh the risk and reward, how does the current valuation appear to lean?

    Most Popular Narrative: 64% Undervalued

    Against Vera Therapeutics’ last close at $27.99, the most followed narrative points to a fair value of $77.50, implying a wide gap that hinges on TRUTAKNA turning into a sizeable IgA nephropathy franchise and the market paying up for that outcome.

    The full two year ORIGIN 3 data set for TRUTAKNA, including a 5.0 ml per year treatment delta in eGFR slope and a 76% risk reduction on a composite kidney endpoint, supports wider physician confidence in BAFF/APRIL modulation. This can expand TRUTAKNA adoption and lift revenue and operating leverage as fixed commercial costs are spread over more treated patients.

    See why 1 investors see Vera Therapeutics as 64% undervalued.

    Result: Fair Value of $77.50 (UNDERVALUED)

    Still, the Vera Therapeutics story can crack if TRUTAKNA uptake trails analyst forecasts or if investors decide a 78.8x future P/E is too rich.

    Find out about the key risks to this Vera Therapeutics narrative.

    Next Steps

    Mixed signals around Vera Therapeutics can feel confusing, so move quickly to review the evidence yourself and then weigh both the upside and downside through the 2 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Vera Therapeutics?

    Do not stop with Vera Therapeutics. Use focused screens to surface other opportunities that match your risk level, income goals, and balance sheet preferences.